Novaliq, AFT Pharmaceuticals enter licensing agreement for NovaTears

Novaliq and AFT Pharmaceuticals have entered a strategic licensing agreement for the commercialization of Novaliq’s NovaTears in Australia and New Zealand, Novaliq announced in a press release.

AFT will have an exclusive license to commercialize NovaTears, used to treat evaporative dry eye diseases, in Australia and New Zealand, and Novaliq will receive an undisclosed upfront payment and royalties on the product’s net sales, under the terms of the agreement.

“NovaTears provides a highly differentiated and clinically validated treatment option that significantly improves the signs and symptoms of evaporative DED and meibomian gland dysfunction,” Christian Roesky, PhD, CEO of Novaliq, said in the release.

Novaliq and AFT Pharmaceuticals have entered a strategic licensing agreement for the commercialization of Novaliq’s NovaTears in Australia and New Zealand, Novaliq announced in a press release.

AFT will have an exclusive license to commercialize NovaTears, used to treat evaporative dry eye diseases, in Australia and New Zealand, and Novaliq will receive an undisclosed upfront payment and royalties on the product’s net sales, under the terms of the agreement.

“NovaTears provides a highly differentiated and clinically validated treatment option that significantly improves the signs and symptoms of evaporative DED and meibomian gland dysfunction,” Christian Roesky, PhD, CEO of Novaliq, said in the release.